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Abstract  
Background: Historically, histiocytic ulcerative (or granulomatous) colitis (HUC) of Boxer dogs was considered 
an idiopathic immune-mediated disease with a poor prognosis. Recent reports of dramatic responses to 
enrofloxacin and the discovery of invasive E. coli within the colonic mucosa of affected Boxer dogs support an 
infectious etiology.   
Hypothesis: Invasive E. coli is associated with colonic inflammation in Boxer dogs with HUC, and eradication 
of intramucosal E. coli correlates with clinical and histologic remission.  
Animals:  7 Boxer dogs with HUC. 
Methods:  Colonic biopsies were obtained at initial evaluation in 7 dogs, and in 5 dogs after treatment with 
enrofloxacin. Biopsies were evaluated by standardized histopathology, and fluorescence in situ hybridization 
(FISH) with probes to eubacteria and E. coli. 
Results: Intramucosal E. coli was present in colonic biopsies of 7/7 Boxers with HUC. Clinical response was 
noted in 7/7 dogs within 2 wks of enrofloxacin given at a mean dose of 7 mg/kg/d for a mean duration of 9.5 
weeks, and was sustained in 6 dogs (mean disease-free interval to date of 45 months). Post-enrofloxacin FISH 
was negative for E. coli in 4/5 dogs. E. coli resistant to enrofloxacin were present in the FISH positive dog that 
relapsed clinically. 
Conclusions and clinical relevance:  The correlation between clinical remission and the eradication of 
mucosally invasive E. coli during treatment with enrofloxacin supports the causal involvement of E. coli in the 
development of HUC in susceptible Boxer dogs. A poor response to enrofloxacin treatment may be due to 
colonization with enrofloxacin-resistant E. coli.  
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Granulomatous colitis (GC) of Boxer dogs was first described by Van Kruiningen in a kennel of Boxer dogs in 
1965.
1 Some subsequent reports of this disease use the term Histiocytic Ulcerative Colitis (HUC),
2-5 and this 
term is more familiar to many veterinarians.
 The clinical hallmarks of the disease are severe large bowel 
diarrhea that is often accompanied by profound weight loss, anemia and hypoalbuminemia.
1-5 HUC, although 
rare, occurs world-wide with reported cases originating from Australia, Japan, North America and Europe.
1-6 
Boxer dogs are most commonly affected although other breeds such as Mastiff, Alaskan Malamute, Doberman 
Pinscher, and French Bulldogs, are sporadically affected.
6-8 
  
The pathognomonic lesion of HUC in Boxer dogs is mucosal infiltration with large numbers of macrophages 
staining positively with period-acid-Schiff (PAS), and is usually accompanied by mucosal ulceration and loss of 
goblet cells.
1 However, both the distribution and severity of lesions within the colon are variable, and in some 
cases they are focally distributed, and macrophages can be scarce and ulceration absent.
9,10 Early reports 
describe a response of 6/9 dogs to chloramphenicol and the presence of intracellular bacteria within 
macrophages.
1,11 However, these findings were poorly reproducible in subsequent studies
9,10 and experimental 
attempts to reproduce HUC,  by infecting Boxer dogs with Mycoplasma spp. isolated from colonic mucosa 
were unsuccessful.
12 In-depth pathological studies describe a loss of goblet cells and an increase in IgG3 and 
IgG4  plasma cells, CD3-T cells, and  L1  (macrophages and polymorphoneulcear granulocytes) and MHCII 
positive cells, similar to ulcerative colitis in people.
13  Thus  HUC  has until recently been regarded as an 
idiopathic immune-mediated disease that typically responds poorly to treatment with empirical therapies such 
as dietary change, antibiotics, and immunosuppressive agents.
4,5  
 
The poor response of HUC to immunosuppression led to a re-appraisal of antibiotic therapy, and there are now 
three independent studies that describe dramatic improvements in clinical signs and histological lesions of 
Boxer dogs treated with antibiotic protocols containing enrofloxacin.
14-16 These observations along with the 
discovery of a bacterial cause for the intestinal infiltration of PAS positive macrophages in people with 
Whipple’s disease
17  initiated the search for  an infectious agent using contemporary culture-independent 
methodologies. Colonic biopsies from affected Boxer dogs (n=13) and controls (n=38) were examined by 
fluorescent in situ hybridization (FISH) with a eubacterial16S rDNA probe. Culture, 16S ribosomal DNA   4 
sequencing, and histochemistry were used to guide subsequent FISH. Intramucosal Gram-negative 
coccobacilli were present in 100% of HUC samples from Boxer dogs but not controls, and invasive bacteria 
hybridized with FISH probes to E. coli.
16  Independent support for  these findings is provided by the 
immunolocalization of E. coli to macrophages within the colons of 10/10 Boxer dogs with HUC.
18 E. coli strains 
isolated from affected Boxer dogs are novel in phylogeny, and have an adherent and invasive phenotype 
(AIEC) similar to strains isolated from people with Crohn’s disease.
16,19,20 These findings suggest that E. coli 
invasion may play a critical role in the initiation and/or progression of HUC  in Boxer dogs, likely facilitated by a 
breed-specific susceptibility.  
 
It is against this background that we sought to determine the temporal association of clinical and histological 
response to the presence or absence of intramucosal E. coli  in Boxer dogs with HUC  before and after 
treatment with enrofloxacin.   5 
Materials and Methods 
Seven Boxers with signs of colitis referred to MUVTH (dogs 1-5) and Cornell University Hospital for Animals 
(dogs 6, 7) between 2002 and 2006 were enrolled in this study. Diagnostic evaluation included hematology, 
serum biochemistry, urinalysis, zinc sulphate fecal flotation, and fecal culture for enteric pathogens, including 
Campylobacter and  Salmonella. Colonic biopsies were obtained at the time of diagnostic evaluation  in all 
seven dogs (endoscopic biopsies) and at variable intervals after enrofloxacin
a treatment in 5 dogs (endoscopic 
in dogs 1,3,4 and 5; full thickness at post-mortem in dog 7). For endoscopic biopsy a minimum of seven to 
twelve colonic biopsies were collected after standard colonoscopic preparation with an oral electrolyte solution
b 
and pre-endoscopic enema with warm water. Enrofloxacin
a was prescribed at dose rates ranging from 4.8 to 
12.8 mg/kg/day for a period of 4-16 weeks, equating to a mean daily dose of 7 mg/kg/day, for a mean duration 
of 9.5 weeks. Two of these dogs (Dogs 1 and 2) have been reported in a previous publication.
14 
 
Histopathology 
In all dogs, haematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) stained paraffin-embedded formalin 
fixed sections of colon were retrospectively evaluated by a veterinary pathologist (SPM) in a blinded manner to 
confirm the original histological diagnosis, and to assess the severity of colitis 
 
Fluorescence in situ hybridization 
Colonic sections were examined by fluorescence in situ hybridization (FISH) in a blinded manner. Eubacterial 
and E coli-specific probes targeting 16S ribosomal rDNA were employed, using established methodologies.
16  
 
Colonic mucosal culture  
Colonoscopic biopsies obtained from dogs 3, 4 and 5 prior to enrofloxacin were stored in Brucella broth with 
30% glycerol at -70°C prior to culture for Shigella, E. coli, Salmonella, Mycobacterium bovis, Mycobacterium 
spp, Chlamydia and Mycosplasma. Colonic biopsies obtained from dog 7 after clinical relapse were cultured for 
E. coli  using methods described previously.
20  Antimicrobial sensitivity of E. coli  was determined by disk 
diffusion.
 21 
   6 
Results 
Initial Evaluation: 
Seven Boxer dogs with a definitive diagnosis of HUC were included in this study (3 neutered females, 2 entire 
female, 1 neutered male, 1 entire male).  The age of onset of clinical signs ranged from 1.5 to 20 months, with 
a mean of 8.8 months.  The age at presentation ranged from 10-24 months, with a mean of 17.4 months.  At 
the time of diagnosis, colitis was graded as severe in 4/7 dogs and moderate in  3/7, typically with large 
numbers of PAS+ macrophages (Figures 1 and 2).  Commonly observed histologic changes were neutrophilic 
infiltration (6  dogs; marked  in dog 6, moderate  in dogs 1,3,7 and  mild in dogs 4 and 5), epithelial 
erosion/ulceration (6 dogs;1, 3-7), crypt hyperplasia and crypt distortion (6 dogs;1-6).  Decreased numbers of 
goblet cells were readily apparent in PAS stained sections from 6/7 dogs (4 severe, dogs 1,3,4,6; 2 moderate, 
dogs 5 and 7). Only one dog (dog 2) had a normal distribution and number of goblet cells.  
FISH analysis was positive for intramucosal E. coli in each of the 7 affected dogs.  
Routine fecal cultures and parasitology were negative for known pathogens. Culture of colonic biopsies from 
dogs 3, 4 and 5 was positive for  E. coli, but negative for Shigella,  Salmonella, Mycobacterium bovis, 
Mycobacterium spp, Chlamydia and Mycosplasma. E. coli isolates were sensitive to a wide range of antibiotics 
including enrofloxacin, gentamicin, amoxicillin-clavulanate and cephalexin. 
 
Clinical response: 
Clinical response was evaluated in 7 Boxer dogs with HUC after treatment with enrofloxacin
a. Five of these 
dogs of these dogs had not responded to previous treatment with sulfasalazine
c  (4), corticosteroids (3), 
erythromycin
d (1) metronidazole
e (2), amoxicillin-clavulanate
f (1), and azathioprine
g (1). Two dogs had received 
no medications prior to enrofloxacin. A positive clinical response (cessation of tenesmus, mucoid feces and 
hematochezia) was noted in 7/7 dogs within 2 wks of enrofloxacin (mean 7 mg/kg/d), and was sustained in 6 
dogs, with a mean disease-free interval to date of 45 months (17-62 months). Dog 7 initially responded well to 
intermittent treatment with enrofloxacin
a (3 courses of approximately 5.0 mg/kg/day for 2-4 weeks) over a 7 
month period, but became unresponsive to enrofloxacin. Culture of colonic biopsies obtained after clinical 
relapse yielded two different strains of E. coli, both of which were resistant to enrofloxacin and gentamicin,
 and 
sensitive to amoxicillin-clavulanate, cefoxitin, ceftriaxone, amikacin and kanamycin. Further treatment with   7 
amoxicillin-clavulanate
f failed to elicit clinical improvement and this dog was euthanatized approximately 4 
weeks later due to the continued severity of clinical signs.  
 
Histopathological response: 
Blinded evaluation of biopsies obtained before and after enrofloxacin
a revealed a marked reduction in the 
severity of inflammation in 4 of the 5 dogs evaluated (dogs 1,3,4 and 5) (Figures 1 and 2).  Histologic remission 
lagged behind clinical remission in each of the responders. In dog 1 (Figure 1) histologic evaluation of 
colonoscopic biopsies 2 weeks after diagnosis showed marked improvement of the initially severe, erosive 
HUC, but a mild infiltration of PAS+ macrophages persisted.  Colonoscopic biopsies collected from this dog on 
a third occasion, 7 months after the initial diagnosis and were histologically within normal limits though rare 
macrophages and crypt distortion persisted (Figure 1).   An impact of HUC on goblet cells  was readily 
appreciated in PAS stained sections from this dog, with marked increases in goblet cells and mucus at 7 
months (Figure 1). In dog 3, colonic histopathology 10 weeks after diagnosis had changed from severe HUC 
with extensive epithelial erosions to mild, lymphoplasmacytic colitis, though small to moderate numbers of PAS 
positive macrophages were observed within the lamina propria and submucosa respectively (Figure 2).  In dog 
4, the initially moderate HUC  with focal epithelial erosions had regressed to mild HUC  with rare PAS+ 
macrophages (predominantly in the submucosa) at repeat histological evaluation of colonic biopsies by 8 
weeks after the initial diagnosis (Figure 2).   The moderate HUC  initially documented in dog 5  had also 
improved, though mild, focal PAS positive macrophages persisted on re-evaluation of colonoscopic biopsies 8 
weeks later (Figure 2).   In dog 7, which relapsed after an initial response to enrofloxacin
a, severe 
granulomatous inflammation and large numbers of PAS+ macrophages was present in biopsies obtained 7 
months after initial evaluation. Partial resolution of epithelial erosion, a more focal distribution of inflammation, 
and a decrease in neutrophils were observed after four weeks of amoxicillin-clavulanate
f  but this did not 
translate into clinical improvement.  
 
Fluorescence in situ hybridization (FISH) post-treatment: 
Post-treatment FISH analysis was negative for intramucosal E. coli in 4/5 dogs (1,3,4,5) at all time points 
evaluated after treatment with enrofloxacin
a (Figures 1 and 3). Intramucosal E. coli was detected in colonic   8 
mucosal biospies from the dog (dog 7) that had become clinically unresponsive to treatment with 
enrofloxacin.  Re-evaluation of colonic biopsies following treatment with amoxicillin-clavulanate
f,  showed 
persistence of intramucosal bacteria, though they did appear reduced in number.   
 
Discussion
 
The clinical response of Boxer dogs with HUC to antibiotic regimens containing enrofloxacin
a strongly suggests 
bacterial involvement in the inflammatory process.
14-16  This possibility is significantly strengthened by the 
recent discovery of invasive E. coli within the colonic mucosa and macrophages of affected Boxer dogs, but 
not dogs with other forms of colitis.
16  Our observations that colonic biopsies obtained during the initial 
diagnostic evaluation of 7 HUC  affected Boxers contained intramucosal E. coli provides independent 
confirmation of these previous findings. The inclusion of dogs from Australia and the USA in the present study, 
and dogs from the UK and USA in the previous study
16 demonstrates that intramucosal colonization of E. coli 
in  HUC  is not a consequence of a geographically restricted infectious agent. In agreement with previous 
reports,
4,5,14,15  we observed a poor clinical response in all dogs treated with various combinations of 
prednisolone,
c  sulfasalazine,
d  and non-enrofloxacin
a  antimicrobials.  We found that enrofloxacin
a  (mean 7 
mg/kg/d) for a mean duration of 9.5 weeks resulted in a positive clinical response in all dogs within two weeks 
of administration, and this was sustained in 6/7 dogs, resulting in mean disease-free interval to date of 45 
months (17-62 mo.). Sustained response correlated with the eradication of invasive intramucosal E. coli. The 
dog that relapsed was positive for intramucosal E. coli that was resistant to enrofloxacin
a. The correlation 
between clinical remission and the eradication of mucosally invasive E. coli during treatment with enrofloxacin
a, 
supports the causal involvement of E. coli in the development of HUC in susceptible Boxer dogs 
 
The association of E. coli with granulomatous intestinal inflammation in Boxer dogs parallels a growing number 
of studies in people with Crohn’s disease that report the presence of E. coli antigens and DNA within affected 
mucosa,
20,22,25 the isolation of higher numbers of invasive E. coli from Crohn’s mucosa,
20,24-26 and increased 
circulating antibodies against E. coli OmpC.
27 It is noteworthy that the E. coli strains isolated from Boxer dogs 
are strikingly similar to those implicated in Crohn’s ileitis,
16-20,24 in that they are able to invade, persist and 
replicate in epithelial cells and macrophages and evoke the production of pro-inflammatory cytokines such as   9 
TNF-α, IFN-γ and IL8.
19,20,28 These characteristics are generally associated with pathogenic bacteria, and it 
seems likely that this emergent group of adherent and invasive E. coli (AIEC)  are opportunistic pathogens able 
to exploit a susceptible individual rather than harmless commensals.
20,25,28 This possibility is consistent with the 
prevailing view that inflammatory bowel disease is the result of an over-exuberant inflammatory response to a 
subset of resident enteric bacteria in a genetically susceptible individual.
29,30  Genetic polymorphisms 
associated with granulomatous intestinal inflammation in people involve defective intracellular processing of 
bacterial components such as polymorphisms in the intracytosolic muramyl dipeptide receptor NOD2, and 
autophagy genes  such as ATG16L1, and an overactive mucosal inflammatory response (e.g. IL-23r promoting 
loss of oral tolerance).
31 Since HUC in dogs is remarkably breed-specific it may be due to a heritable anomaly 
in Boxer dogs that confers susceptibility to invasion and persistence of AIEC within the colonic mucosa. As 
Boxer dogs are also prone to other granulomatous diseases such as intestinal and systemic protothecosis and 
cutaneous intracellular mycobacteria (canine leproid granuloma syndrome),
32,33  it is possible that Boxers have 
a genetic defect in how they respond to granuloma-inducing microorganisms in general, e.g. defective bacterial 
killing. Further study is needed to identify the host and bacterial factors related to invasion and persistence of 
E. coli in HUC susceptible Boxers. 
 
Our finding that clinical remission in response to enrofloxacin
a correlates with the eradication of invasive E.coli 
and precedes complete histologic resolution of inflammation highlights the importance of eliminating E. coli 
infection in Boxers with HUC. Serial evaluation of dog 1, where the ongoing inflammation observed at 2 weeks 
had almost completely resolved at 7 months suggests the lag between bacterial eradication and normalization 
of colonic histology reflects the time taken to heal and remodel the severely damaged mucosa. These 
observations are similar to findings in people with Whipple’s disease where regression of PAS positivity lags 
behind eradication of Trophyrema whipplei.
34  
 
 
In the present study, resistance to enrofloxacin
a was demonstrated in two E. coli strains isolated from the 
colonic mucosa of a dog whose clinical signs recurred after an initial response to enrofloxacin. The 
development of resistance to enrofloxacin
a has been extensively demonstrated in dogs with E. coli and other   10 
Enterobacteriaceae infections
35-38 and often involves acquisition of resistance plasmids.
38 Interestingly, the 
dog that relapsed had received several short courses of treatment with enrofloxacin (2-4 weeks) and it is 
possible that repeated withdrawal of enrofloxacin
a  prior to complete eradication of infection facilitated 
recrudescence and subsequently development of enrofloxacin
a resistance. Short-term treatment of this dog 
with amoxicillin-clavulanate
g, based on the results of antimicrobial susceptibility testing, resulted in a reduction 
in intramucosal E. coli and partial histologic improvement, but this did not translate to clinical improvement. 
While it is possible that a longer duration of treatment may have been effective it is important to consider that 
differences in the ability of antibiotics to penetrate infected macrophages may also affect outcome. Evaluation 
of the ability of antibiotics (at peak serum concentrations) to kill E. coli isolated from colonic Crohn’s disease 
within J774-A1 macrophages indicates greatest efficacy of ciprofloxacin, with decreasing impact of rifampicin, 
tetracycline, trimethoprim, clarithromycin and azithromycin.
39  This study also found the combination of 
ciprofloxacin, tetracycline and trimethoprim was more effective than ciprofloxacin alone, and that ampicillin was 
not effective against intra-cellular CD associated E. coli.  Hence, the ability to effectively penetrate and kill E. 
coli within macrophages may explain the positive response of HUC of Boxers to enrofloxacin, and also to 
chloramphenicol,
1 and the negative response of the dog in the present study to amoxicillin-clavulanate
g. To 
optimize the treatment of HUC of Boxers in the future it would seem prudent that FISH and colonic mucosal 
culture are performed as part of the diagnostic evaluation of Boxer dogs suspected of HUC. This would enable 
antimicrobial selection based on sensitivity testing of mucosal E. coli isolated from FISH positive individuals 
and their ability to penetrate tissues and macrophages. Based on the results of the present and previous 
studies,
14-16 Boxer dogs with enrofloxacin sensitive HUC should be treated for at least 6 to 8 weeks at doses of 
5-10mg/kg body weight /day.  
 
Previous reports have documented resolution or improvement of clinical signs in some affected Boxers 
managed with dietary therapy and sulfasalazine.
4,5  Mesalamine, but not hydrocortisone, at therapeutic 
concentrations has recently been shown to inhibit MAPK-dependent IL-8 release in response to adherent and 
invasive IBD and colon cancer E. coli isolates in vitro, and it may have some therapeutic benefit in vivo.
40 
However, as the dogs in this present study that received sulfasalazine
d failed to respond, a meaningful effect of   11 
sulfasalazine
d in dogs with severe HUC seems unlikely. Whether sulfasalazine
d has a role in treating Boxers 
with mild HUC or as an adjunct to enrofloxacin
a remains to be determined 
 
In conclusion, this case series serves to corroborate the association of mucosally invasive E. coli with HUC in 
Boxer dogs and the responsiveness of this disease to enrofloxacin
a. The correlation between clinical remission 
and eradication of mucosally invasive E. coli  supports the potential causal involvement of E. coli  in the 
development of HUC  in susceptible Boxer dogs. As clinical relapse was associated with enrofloxacin
a 
resistance, we suggest that sensitivity profiles of mucosal E. coli and the ability of antibiotics to penetrate 
macrophages are used to guide antimicrobial selection. 
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Legends for Figures: 
Figure 1. Colonic histopathology and fluorescence in situ hybridization (FISH) before and after 
treatment of HUC with enrofloxacin 
Colonic biopsies from dog 1 at initial diagnosis were dominated by PAS positive macrophages (a) and 
invasive intramucosal bacteria that hybridized with a Cy-3 labeled probe to E. coli (b: bacteria are 
orange, DAPI stained nuclei are blue). After 2 wks of enrofloxacin mucosal infiltration with PAS 
positive macrophages persists (c) but no invasive bacteria are visualized by FISH (d). 7 months after 
diagnosis, the infiltration of PAS positive macrophages had resolved (though occasional PAS positive 
macrophages remained), goblet cells containing abundant PAS staining mucus were apparent (e), 
and FISH (f) remained negative. 
 
Figure 2. Colonic histopathology before and after treatment of HUC with enrofloxacin 
H&E and PAS stained sections of endoscopic colonic biopsies from dogs 2,3 and 4 before (a, c, e) 
and eight to ten weeks after treatment with enrofloxacin (b, d, f). In untreated HUC (a, c, e) epithelial 
erosion, loss of glandular structure and marked cellular infiltration with PAS positive macrophages 
(insets) were readily apparent. After treatment with enrofloxacin (b, d, f) histological abnormalities had 
markedly improved in all three dogs, though  small numbers of PAS positive macrophages and 
infiltrates of lymphocytes and plasma cells were still present. An increase in PAS positive goblet cells 
was observed in all three dogs post treatment (insets, b,d,f). 
 
Figure 3: Fluorescence in situ hybridization (FISH) before and after treatment of HUC with 
enrofloxacin 
Fluorescence in situ hybridization (FISH) of colonic biopsies from dogs 2, 3 and 4 prior to enrofloxacin 
(a, c, e) revealed multifocal intramucosal bacteria that hybridized with a Cy-3 labeled probe to E. coli 
(bacteria are orange, DAPI stained nuclei are blue). Many of the E. coli  appeared to be within   16 
macrophages (insets a, c, e). After treatment with enrofloxacin sections from all 3 dogs (b, d, f), 
were FISH negative.   
 
 